Antihypertensive medicine sales in Spain for 2023 stood at 173.4 million USD PPP. Forecasts for the years 2024 through 2028 project stable sales values, remaining constant at 173.4 million USD PPP through 2026 and slightly decreasing to 173.3 million USD PPP in 2027 and 2028. This indicates a negligible year-on-year variation for the forecasted period.
Overall, the compound annual growth rate (CAGR) over the last five years shows an almost zero growth rate, reflecting a stable market environment.
Future trends to watch for include potential shifts in healthcare policies, the introduction of new competitive treatments, and demographic changes affecting hypertension prevalence. Monitoring these variables will be crucial for anticipating any market fluctuations.
